- Home
- SNYR vs PMN Comparison
SNYR vs PMN Comparison
Compare SNYR & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNYR
- PMN
- Stock Information
- Founded
- SNYR 2010
- PMN 2004
- Country
- SNYR United States
- PMN Canada
- Employees
- SNYR N/A
- PMN N/A
- Industry
- SNYR
- PMN Pharmaceuticals and Biotechnology
- Sector
- SNYR
- PMN Health Care
- Exchange
- SNYR NYSE
- PMN Nasdaq
- Market Cap
- SNYR 16.6M
- PMN 17.0M
- IPO Year
- SNYR N/A
- PMN N/A
- Fundamental
- Price
- SNYR $2.65
- PMN $0.50
- Analyst Decision
- SNYR Strong Buy
- PMN Strong Buy
- Analyst Count
- SNYR 1
- PMN 2
- Target Price
- SNYR $10.00
- PMN $4.50
- AVG Volume (30 Days)
- SNYR 87.8K
- PMN 48.8K
- Earning Date
- SNYR 05-15-2025
- PMN 08-07-2025
- Dividend Yield
- SNYR N/A
- PMN N/A
- EPS Growth
- SNYR N/A
- PMN N/A
- EPS
- SNYR 0.30
- PMN N/A
- Revenue
- SNYR $33,592,914.00
- PMN N/A
- Revenue This Year
- SNYR $37.83
- PMN N/A
- Revenue Next Year
- SNYR $18.39
- PMN N/A
- P/E Ratio
- SNYR $8.74
- PMN N/A
- Revenue Growth
- SNYR N/A
- PMN N/A
- 52 Week Low
- SNYR $0.12
- PMN $0.47
- 52 Week High
- SNYR $10.00
- PMN $2.37
- Technical
- Relative Strength Index (RSI)
- SNYR N/A
- PMN 45.69
- Support Level
- SNYR N/A
- PMN $0.48
- Resistance Level
- SNYR N/A
- PMN $0.53
- Average True Range (ATR)
- SNYR 0.00
- PMN 0.04
- MACD
- SNYR 0.00
- PMN 0.00
- Stochastic Oscillator
- SNYR 0.00
- PMN 25.00
About SNYR SYNERGY CHC CORP
Synergy CHC Corp is a provider of consumer health care, beauty, and lifestyle products. It is engaged in the business of marketing and distributing consumer branded products through various distribution channels in the health and wellness industry. The company's products include FOCUSfactor, Flat Tummy Tea, Hand MD, and Neuragen amongst others. Flat Tummy is a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their nutrition and weight management goals.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.